French test of leftover tumor DNA in the blood after pancreatic cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational project within the European GUIDE.MRD effort to confirm that circulating tumor DNA (ctDNA) after curative‑intent treatment indicates minimal residual disease in pancreatic ductal adenocarcinoma (PDAC). Adults with resectable PDAC scheduled for curative surgery at CHU de Montpellier will be enrolled and provide serial blood samples (liquid biopsies) after surgery and after adjuvant chemotherapy. Standardized ctDNA assays developed by the consortium will be used to determine ctDNA detection status and those results will be correlated with disease‑free survival and recurrence timing. The goal is to harmonize ctDNA testing methods and produce clinically useful data to guide follow‑up and treatment decisions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pancreatic ductal adenocarcinoma, according to the assessment of the MDT.
* Age 18 years or older.
* Scheduled for curative intent surgical resection.

Exclusion Criteria:

* Hereditary pancreatic cancer.
* Verified distant metastases.
* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and/or otherwise considered by the Investigator to be unlikely to complete the study.
* Other cancers (excluding prior pancreatic cancer or skin cancer other than melanoma) within 3 years from eligibility screening.
* Pregnant or nursing woman, or in childbearing age and not willing to use contraception
* Adult subject to a legal protection
* Not covered by Health insurance
* Patient unable to understand and sign written informed consent.

Where it's running

• CHU de Montpellier
  Montpellier, Hérault, France Recruiting

Study contacts

• Principal investigator: Thomas BARDOL, M.D. — University Hospital, Montpellier
• Study coordinator: Catherine ALIX-PANABIERES, Ph.D
• Email: c-panabieres@chu-montpellier.fr
• Phone: +33411759931

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ctDNA blood tests to guide treatment in colorectal cancer with liver metastases

  A study using blood tests that look for tumor DNA to help decide which patients with colorectal cancer that has spread to the liver need more treatment after surgery.

  Recruiting at 2 sites University Hospital, Montpellier · Montpellier and 1 other locations · NCT06287723

• Early detection of pancreatic cancer using exosome-based biomarkers

  This study is testing a new way to find pancreatic cancer early by looking at tiny particles in the blood that carry specific markers.

  Recruiting at 11 sites City of Hope Medical Center · Phoenix, Arizona and 12 other locations · NCT06388967

• French testing of blood-based ctDNA to find leftover cancer after surgery in Stage III colorectal cancer

  We will test whether blood-based ctDNA can find leftover cancer after surgery in people with Stage III colorectal cancer to help guide additional treatment.

  Recruiting University Hospital, Montpellier · Montpellier, Hérault · NCT06287814

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• ctDNA methylation-guided adjuvant therapy after removing colorectal liver metastases

  This trial tests whether using a blood test that detects ctDNA methylation after surgery can guide adjuvant therapy for patients who had colorectal cancer spread to the liver and were operated on with no remaining disease.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07917104

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.